NCT04177095 - Immune Monitoring to Facilitate Belatacept Monotherapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 11, 2020

Primary Completion Date

September 30, 2021

Study Completion Date

June 1, 2023

Conditions

Kidney Transplant RejectionImmunosuppression

Interventions

DIAGNOSTIC_TEST

Allosure

Monthly monitoring of dd-cfDNA levels in blood

DRUG

Immunosuppression reduction

Stepwise reduction in the dose, and ultimate discontinuation of, all non-belatacept immunosuppression (mycophenolate, sirolimus, everolimus, prednisone) guided by monitoring of Allosure and Trugraf results

DIAGNOSTIC_TEST

Trugraf

Monthly monitoring of Trugraf result

Trial Locations (1)

02114

Massachusetts General Hospital, Boston